281 related articles for article (PubMed ID: 26595814)
1. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.
Dewaele M; Tabaglio T; Willekens K; Bezzi M; Teo SX; Low DH; Koh CM; Rambow F; Fiers M; Rogiers A; Radaelli E; Al-Haddawi M; Tan SY; Hermans E; Amant F; Yan H; Lakshmanan M; Koumar RC; Lim ST; Derheimer FA; Campbell RM; Bonday Z; Tergaonkar V; Shackleton M; Blattner C; Marine JC; Guccione E
J Clin Invest; 2016 Jan; 126(1):68-84. PubMed ID: 26595814
[TBL] [Abstract][Full Text] [Related]
2. Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.
Bardot B; Bouarich-Bourimi R; Leemput J; Lejour V; Hamon A; Plancke L; Jochemsen AG; Simeonova I; Fang M; Toledo F
Oncogene; 2015 May; 34(22):2943-8. PubMed ID: 25088193
[TBL] [Abstract][Full Text] [Related]
3. MDM4 is a key therapeutic target in cutaneous melanoma.
Gembarska A; Luciani F; Fedele C; Russell EA; Dewaele M; Villar S; Zwolinska A; Haupt S; de Lange J; Yip D; Goydos J; Haigh JJ; Haupt Y; Larue L; Jochemsen A; Shi H; Moriceau G; Lo RS; Ghanem G; Shackleton M; Bernal F; Marine JC
Nat Med; 2012 Aug; 18(8):1239-47. PubMed ID: 22820643
[TBL] [Abstract][Full Text] [Related]
4. An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3.
Wang X; Yan L; Guo J; Jia R
Int Immunopharmacol; 2024 Jan; 126():111280. PubMed ID: 38043270
[TBL] [Abstract][Full Text] [Related]
5. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.
Yano K; Takahashi RU; Shiotani B; Abe J; Shidooka T; Sudo Y; Yamamoto Y; Kan S; Sakagami H; Tahara H
J Biol Chem; 2021 Jul; 297(1):100882. PubMed ID: 34144037
[TBL] [Abstract][Full Text] [Related]
6. MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.
Hüllein J; Słabicki M; Rosolowski M; Jethwa A; Habringer S; Tomska K; Kurilov R; Lu J; Scheinost S; Wagener R; Huang Z; Lukas M; Yavorska O; Helfrich H; Scholtysik R; Bonneau K; Tedesco D; Küppers R; Klapper W; Pott C; Stilgenbauer S; Burkhardt B; Löffler M; Trümper LH; Hummel M; Brors B; Zapatka M; Siebert R; Kreuz M; Keller U; Huber W; Zenz T
Cancer Res; 2019 Jun; 79(12):3125-3138. PubMed ID: 31000522
[TBL] [Abstract][Full Text] [Related]
7. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
8. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
9. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
10. Tumorigenesis promotes Mdm4-S overexpression.
Pant V; Larsson CA; Aryal N; Xiong S; You MJ; Quintas-Cardama A; Lozano G
Oncotarget; 2017 Apr; 8(16):25837-25847. PubMed ID: 28460439
[TBL] [Abstract][Full Text] [Related]
11. MDM4 is a rational target for treating breast cancers with mutant p53.
Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
[TBL] [Abstract][Full Text] [Related]
12. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
Roh JL; Park JY; Kim EH
Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
[TBL] [Abstract][Full Text] [Related]
13. Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides.
Wang Z; Jeon HY; Rigo F; Bennett CF; Krainer AR
Open Biol; 2012 Oct; 2(10):120133. PubMed ID: 23155487
[TBL] [Abstract][Full Text] [Related]
14. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.
Mancini F; Pieroni L; Monteleone V; Lucà R; Fici L; Luca E; Urbani A; Xiong S; Soddu S; Masetti R; Lozano G; Pontecorvi A; Moretti F
Oncogene; 2016 Jan; 35(2):228-40. PubMed ID: 25961923
[TBL] [Abstract][Full Text] [Related]
15. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
16. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
17. Identification and expression of a novel MDM4 splice variant in human glioma.
Wang X; Sheng P; Guo X; Wang J; Hou L; Hu G; Luo C; Dong Y; Lu Y
Brain Res; 2013 Nov; 1537():260-6. PubMed ID: 23994448
[TBL] [Abstract][Full Text] [Related]
18. Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.
Fang M; Simeonova I; Bardot B; Lejour V; Jaber S; Bouarich-Bourimi R; Morin A; Toledo F
Oncogene; 2014 Mar; 33(10):1336-9. PubMed ID: 23474762
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.
Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL
Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706
[TBL] [Abstract][Full Text] [Related]
20. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
